Validation Talks #7 - How the FDA Catches Fake Drug Data | #Validfor

FDA’s guidance on data integrity is critical for ensuring that pharmaceutical companies maintain accurate, complete, and reliable data in compliance with GxP regulations.

In this video, we break down FDA data integrity guidance, what it means in practice, and how organizations can align their processes with regulatory expectations such as 21 CFR Part 11 and ALCOA+ principles.

As regulatory scrutiny increases, managing data integrity with manual and fragmented systems becomes more challenging. Validfor helps life sciences teams align with FDA expectations by connecting requirements, risks, tests, and changes in one structured and traceable validation lifecycle.

With Validfor, organizations can improve traceability, strengthen compliance, and maintain audit-ready systems while reducing the risk of data integrity issues.

If you work in pharma, biotech, or medtech, understanding FDA data integrity guidance is essential for ensuring compliance and building trustworthy systems.

🔍 In this video:
• What is FDA data integrity guidance?
• Key requirements and expectations
• Role of 21 CFR Part 11 and ALCOA+
• Common compliance risks
• How digital validation supports regulatory alignment

📖 Read the full guide:
https://validfor.com/fdas-guidance-on...

🚀 Explore Validfor:
https://validfor.com/get-a-demo/

#FDA #DataIntegrity #Pharma #LifeSciences #GxP #ALCOA #ALCOAPlus #21CFRPart11 #Compliance #PharmaTech #DigitalValidation #Validation #AuditReady #RegTech #AIValidation #Validfor

Видео Validation Talks #7 - How the FDA Catches Fake Drug Data | #Validfor канала Validfor